A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

December 2, 2022

Study Completion Date

January 27, 2023

Conditions

B-cell Tumors

Interventions

DRUG

SHR1459 tablet

100 mg/tablet; administered orally

DRUG

Efavirenz tablet

600 mg/tablet; administered orally

Trial Locations (1)

The First People's Hospital of Lianyungang, Lianyungang

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY